encouraged to use the Version of Record that, when published, will replace this version. The most /BCJ

Σχετικά έγγραφα
encouraged to use the Version of Record that, when published, will replace this version. The most /BCJ

encouraged to use the Version of Record that, when published, will replace this version. The most /BCJ BIOCHEMICAL JOURNAL

encouraged to use the Version of Record that, when published, will replace this version. The most /BCJ

The Nottingham eprints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

Longitudinal Changes in Component Processes of Working Memory

Enzymatic Synthesis of Dithiolopyrrolone Antibiotics Using Cell-Free Extract of Saccharothrix

Development and Verification of Multi-Level Sub- Meshing Techniques of PEEC to Model High- Speed Power and Ground Plane-Pairs of PFBS

Supplementary Materials: A Preliminary Link between Hydroxylated Metabolites of Polychlorinated Biphenyls and Free Thyroxin in Humans

ΕΛΛΗΝΙΚΗ ΔΗΜΟΚΡΑΤΙΑ Ανώτατο Εκπαιδευτικό Ίδρυμα Πειραιά Τεχνολογικού Τομέα. Ξένη Ορολογία. Ενότητα 6: Working Capital

Cellular Physiology and Biochemistry

Congruence Classes of Invertible Matrices of Order 3 over F 2

상대론적고에너지중이온충돌에서 제트입자와관련된제동복사 박가영 인하대학교 윤진희교수님, 권민정교수님

This is an electronic reprint of the original article. This reprint may differ from the original in pagination and typographic detail.

< (0.999) Graft (0.698) (0.483) <0.001 (0.698) (<0.001) (<0.001) 3 months (0.999) (0.483) (<0.001) 6 months (<0.

MathCity.org Merging man and maths

Ψηφιακή ανάπτυξη. Course Unit #1 : Κατανοώντας τις βασικές σύγχρονες ψηφιακές αρχές Thematic Unit #1 : Τεχνολογίες Web και CMS

the total number of electrons passing through the lamp.

w o = R 1 p. (1) R = p =. = 1

Conjoint. The Problems of Price Attribute by Conjoint Analysis. Akihiko SHIMAZAKI * Nobuyuki OTAKE

ΠΡΟΣΚΛΗΣΗ ΕΚΔΗΛΩΣΗΣ ΕΝΔΙΑΦΕΡΟΝΤΟΣ

derivation of the Laplacian from rectangular to spherical coordinates

Th, Ra, Rn, Po, Pb, Bi, & Tl K x-rays. Rn Kα1. Rn Kα2. 93( 227 Th)/Rn Kβ3. Ra Kα2. Po Kα2 /Bi K α1 79( 227 Th)/Po Kα1. Ra Kα1 /Bi K β1.

Προσωπική Aνάπτυξη. Ενότητα 2: Διαπραγμάτευση. Juan Carlos Martínez Director of Projects Development Department

Προσωπική Aνάπτυξη. Ενότητα 4: Συνεργασία. Juan Carlos Martínez Director of Projects Development Department

New hybrid functional materials based on carbon: synthesis, characterization and study of properties Zygouri, Panagiota

TERMINATIONS FOR SPACE / THERMAL VACUUM APPLICATIONS

Comparison of carbon-sulfur and carbon-amine bond in therapeutic drug: -S-aromatic heterocyclic podophyllum derivatives display antitumor activity

CHAPTER 12: PERIMETER, AREA, CIRCUMFERENCE, AND 12.1 INTRODUCTION TO GEOMETRIC 12.2 PERIMETER: SQUARES, RECTANGLES,

Selective mono reduction of bisphosphine

Ψηφιακή ανάπτυξη. Course Unit #1 : Κατανοώντας τις βασικές σύγχρονες ψηφιακές αρχές Thematic Unit #1 : Τεχνολογίες Web και CMS

14.5mm 14.5mm

Characterization Report

65W PWM Output LED Driver. IDLV-65 series. File Name:IDLV-65-SPEC

ΠΡΟΣΚΛΗΣΗ ΕΚΔΗΛΩΣΗΣ ΕΝΔΙΑΦΕΡΟΝΤΟΣ

Mathematical model for HIV spreads control program with ART treatment

Electrical Specifications at T AMB =25 C DC VOLTS (V) MAXIMUM POWER (dbm) DYNAMIC RANGE IP3 (dbm) (db) Output (1 db Comp.) at 2 f U. Typ.

Smaller. 6.3 to 100 After 1 minute's application of rated voltage at 20 C, leakage current is. not more than 0.03CV or 4 (µa), whichever is greater.

Εγκατάσταση λογισμικού και αναβάθμιση συσκευής Device software installation and software upgrade

"#$%&#%$'(!)*!+$',+-.$+/!,%&/')0$)#'.,(!1.#2!#$.02)(02+#'!3(456!$'-'+/!+!

Scrum framework: Ρόλοι

High Performance Voltage Controlled Amplifiers Typical and Guaranteed Specifications 50 Ω System

Γεωπονικό Πανεπιςτήμιο Αθηνών Τμήμα Αξιοποίηςησ Φυςικών Πόρων και Γεωργικήσ Μηχανικήσ

65W PWM Output LED Driver. IDPV-65 series. File Name:IDPV-65-SPEC

Supporting Information. Introduction of a α,β-unsaturated carbonyl conjugated pyrene-lactose hybrid

IDPV-45 series. 45W PWM Output LED Driver. File Name:IDPV-45-SPEC S&E

Math 6 SL Probability Distributions Practice Test Mark Scheme

ΑΛΕΞΑΝΔΡΟΣ ΠΑΛΛΗΣ SCHOOLTIME E-BOOKS

Multilayer Ceramic Chip Capacitors

SMD Power Inductor. - SPRH127 Series. Marking. 1 Marking Outline: 1 Appearance and dimensions (mm)

Instruction Execution Times

Aluminum Electrolytic Capacitors (Large Can Type)

Üzleti élet Rendelés. Rendelés - Megrendelés. Rendelés - Visszaigazolás. Hivatalos, kísérleti

Multilayer Ceramic Chip Capacitors

CORDIC Background (2A)

Supplementary Appendix

MRL HYDRAULIC LIFTS TYPE:

Supplementary Figure 1

RECIPROCATING COMPRESSOR CALCULATION SHEET ISOTHERMAL COMPRESSION Gas properties, flowrate and conditions. Compressor Calculation Sheet

(1) Describe the process by which mercury atoms become excited in a fluorescent tube (3)

Oil grooved pads PFO series

ΠΑΝΔΠΗΣΖΜΗΟ ΠΑΣΡΩΝ ΣΜΖΜΑ ΖΛΔΚΣΡΟΛΟΓΩΝ ΜΖΥΑΝΗΚΩΝ ΚΑΗ ΣΔΥΝΟΛΟΓΗΑ ΤΠΟΛΟΓΗΣΩΝ ΣΟΜΔΑ ΤΣΖΜΑΣΩΝ ΖΛΔΚΣΡΗΚΖ ΔΝΔΡΓΔΗΑ

RANGE OF APPLICATION TRACTION LIFT MR HIGH SPEED. ver sion 1.1 / web: info@doppler.gr

C4C-C4H-C4G-C4M MKP Series AXIAL CAPACITORS PCB APPLICATIONS

Robust Network Interdiction with Invisible Interdiction Assets

Jeux d inondation dans les graphes

Πώς μπορεί κανείς να έχει έναν διερμηνέα κατά την επίσκεψή του στον Οικογενειακό του Γιατρό στο Ίσλινγκτον Getting an interpreter when you visit your

First Sensor Quad APD Data Sheet Part Description QA TO Order #

Section 8.3 Trigonometric Equations

Advanced Subsidiary Unit 1: Understanding and Written Response

ΔΙΟΙΚΗΣΗ ΔΙΕΘΝΩΝ ΕΠΙΧΕΙΡΗΣΕΩΝ

Ηλεκτρονικοί Υπολογιστές IV

Εργαστήριο Ανάπτυξης Εφαρμογών Βάσεων Δεδομένων. Εξάμηνο 7 ο

SMD Transient Voltage Suppressors

Προσωπική Aνάπτυξη. Ενότητα 1: Ηγεσία και ενδυνάμωση. Juan Carlos Martínez Director of Projects Development Department

ΣΟΡΟΠΤΙΜΙΣΤΡΙΕΣ ΕΛΛΗΝΙΔΕΣ

1) Formulation of the Problem as a Linear Programming Model

Scrum framework: Γεγονότα

Defects in Hard-Sphere Colloidal Crystals

Quick Installation Guide

Homework 3 Solutions

The Simply Typed Lambda Calculus

Aluminum Electrolytic Capacitors

«ΨΥΧΙΚΗ ΥΓΕΙΑ ΚΑΙ ΣΕΞΟΥΑΛΙΚΗ» ΠΑΝΕΥΡΩΠΑΪΚΗ ΕΡΕΥΝΑ ΤΗΣ GAMIAN- EUROPE

Supplementary Information. Living Ring-Opening Polymerization of Lactones by N-Heterocyclic Olefin/Al(C 6 F 5 ) 3

CORDIC Background (4A)

Reforming the Regulation of Political Advocacy by Charities: From Charity Under Siege to Charity Under Rescue?

ΠΕΡΙΕΧΟΜΕΝΑ. Κεφάλαιο 1: Κεφάλαιο 2: Κεφάλαιο 3:

ΠΡΟΔΡΟΜΑ ΑΠΟΤΕΛΕΣΜΑΤΑ ΠΡΟΟΠΤΙΚΗΣ ΜΕΛΕΤΗΣ

PHOS π 0 analysis, for production, R AA, and Flow analysis, LHC11h

A strategy for the identification of combinatorial bioactive compounds. contributing to the holistic effect of herbal medicines

5.4 The Poisson Distribution.

Business Opening. Very formal, recipient has a special title that must be used in place of their name

ΕΦΗΜΕΡΙ Α ΤΗΣ ΚΥΒΕΡΝΗΣΕΩΣ

k A = [k, k]( )[a 1, a 2 ] = [ka 1,ka 2 ] 4For the division of two intervals of confidence in R +

ΖΕΡΔΑΛΗΣ ΣΩΤΗΡΙΟΣ ΤΟ ΟΥΤΙ ΣΤΗ ΒΕΡΟΙΑ (1922-ΣΗΜΕΡΑ) ΘΕΣΣΑΛΟΝΙΚΗ

ΕΦΗΜΕΡΙΣ ΤΗΣ ΚΥΒΕΡΝΗΣΕΩΣ

MSM Men who have Sex with Men HIV -

Spatiotemporal footprint of the WNV in Greece : Analysis & Risk Αssessment in a GIS Εnvironment

Model NAST (Separable Type)

Transcript:

Biochemical Journal: this is an Accepted Manuscript, not the final Version of Record. You are encouraged to use the Version of Record that, when published, will replace this version. The most up-to-date version is available at http://dx.doi.org/1.142/bcj21783. Please cite using the DOI 1.142/BCJ21783 ACCEPTED MANUSCRIPT which Use of Archiving the open article access is published. articles is Archiving permitted of based non-open on the access terms articles of the specific is permitted Creative in accordance Commons Licence with the under Policy of Portland Press ( http://www.portlandpresspublishing.com/content/open-access-policy#archiving).

μ

μ μμ μ

μ

μ μ μ μ

μ μ μ μ μ μ

μ μ μ μ

Figure 1 LRRK2 RAB1 NEUTROPHILS Eosinophil Basophil NK cells NK (dim) NK (bright) DC s Dendritic (plasmacytoid) Dendritic (myeloid) CD8 (effector memory RA) CD8 (effector memory) CD8 (central memory) CD8 (naive) Tregs (memory) Tregs (naive) PBMC T cells Th2 Th17 Th1 CD4 (effector memory RA) CD4 (effector memory) CD4 (central memory) CD4 (naive) B cells B (plasma) B (memory) B (naive) monocytes Monocyte (non classical) Monocyte (intermediate) Monocyte (classical) 1x1 5 2x1 5 3x1 5 4x1 5 5x1 5 2x1 6 4x1 6 6x1 6 Protein copies per cell Protein copies per cell

Figure 2 A Donor 1 2 3 4 5 6 7 8 9 1 11 12 Gender Male Female Male Male Female Female Male Male Female Male Male Female Viability 98.9% 99.6% 99.5% 99.2% 99.4% 99.5% 99.1% 98.8% 98.9% 99.2% 99.8% 99.7% Purity 98% 99.3% 97.2% 98.7% 99% 99.1% 99% 96.6% 99% 99.3% 99% 99.8% Total protein amount (mg/condition) 1.1.36.48.59.72.56.71.67.21.79.26 1.4 B 2 Total LRRK2 Full Length (i) Donor 1 2 3 4 5 6 7 8 9 1 11 12 MLi-2: - + - + - + - + - + - + - + - + - + - + - + - + 25 15 25 15 25 15 LRRK2 (C-Terminus) LRRK2 (N-Terminus) LRRK2 ps935 37 GAPDH Total LRRK2/GAPDH (286kDa species) 1 -+-+-+-+-+-+-+-+-+-+-+-+ Donor: 1 2 3 4 5 6 7 8 9 1 11 12 Total LRRK2/GAPDH (2kDa species) 2 1 Total LRRK2 2 kda species (ii) -+-+-+-+-+-+-+-+-+-+-+-+ Donor: 1 2 3 4 5 6 7 8 9 1 11 12 C LRRK2 ps935/total LRRK2 (286kDa species) 2 1 Phospho-Ser935 LRRK2 Full Length (iii) -+-+-+-+-+-+-+-+-+-+-+-+ Donor: 1 2 3 4 5 6 7 8 9 1 11 12 Donor 1 2 3 4 5 6 7 8 9 1 11 12 MLi-2: - + - + - + - + - + - + - + - + - + - + - + - + 25 25 37 3 Phospho-Rab1 vs GAPDH (ii) prab1 Rab1 GAPDH LRRK2 ps935/ Total LRRK2 (2kDa species) 2 1 Phospho-Ser935 LRRK2 2 kda species (iv) -+-+-+-+-+-+-+-+-+-+-+-+ Donor: 1 2 3 4 5 6 7 8 9 1 11 12 Total Rab1/GAPDH 2 1 Total Rab1 (i) -+-+-+-+-+-+-+-+-+-+-+-+ Donor: 1 2 3 4 5 6 7 8 9 1 11 12 3 Phospho-Rab1 vs Total Rab1 (iii) prab1/gapdh 2 1 prab1/total Rab1 2 1 -+-+-+-+-+-+-+-+-+-+-+-+ Donor: 1 2 3 4 5 6 7 8 9 1 11 12 -+-+-+-+-+-+-+-+-+-+-+-+ Donor: 1 2 3 4 5 6 7 8 9 1 11 12

Figure 3 Control G219S Control G219S Donor 12 Donor 17 Donor 23 Donor 5 Donor 2 Donor 7 Donor 1 Donor 18 Donor 13 Donor 21 Donor 19 Donor 26 Donor 22 MLi-2: - - + + - - + + - - + + - - + + - - + + - - + + - - + + - - + + - - + + - - + + - - + + - - + + - - + + 25 25 prab1 LRRK2 ps935 25 25 Rab1 LRRK2 37 Control Idiopathic Control Idiopathic Donor 14 Donor 16 Donor 6 Donor 24 Donor 15 Donor 3 Donor 9 Donor 11 Donor 1 Donor 4 Donor 2 Donor 8 Donor 25 MLi-2: - - + + - - + + - - + + - - + + - - + + - - + + - - + + - - + + - - + + - - + + - - + + - - + + - - + + 25 25 GAPDH prab1 LRRK2 ps935 25 25 Rab1 LRRK2 37 GAPDH

Figure 4 A B C D Total LRRK2/GAPDH (Full length) Total LRRK2/GAPDH (2 kda species) LRRK2 ps935/total LRRK2 (Full length) Total Rab1/GAPDH 1 4 3 2 1 4 3 2 1 8 6 4 2 Donor 13 Donor 17 Donor 5 Donor 13 Donor 11 Donor 17 Donor 21 Donor 5 Donor 13 Control G219S Idiopathic 2.5 Control 2. 1.5 1..5. Donor 17 Donor 5 Donor 12 G219S Idiopathic Control G219S Idiopathic Donor 14 Donor 21 Donor 1 Donor 11 Donor 6 Donor 23 Donor 12 Donor 16 Donor 18 Donor 9 Donor 22 Donor 1 Donor 7 Donor 26 Donor 2 Donor 19 Donor 14 Donor 21 Donor 1 Donor 5 Donor 6 Donor 12 Donor 9 Donor 23 Donor 16 Donor 18 Donor 22 Donor 26 Donor 1 Donor 21 Donor 14 Donor 1 Donor 16 Donor 23 Donor 13 Donor 6 Donor 9 Donor 11 Donor 18 Donor 22 Donor 1 Donor 23 Donor 1 Donor 11 Donor 9 Donor 17 Donor 18 Donor 6 Donor 12 Donor 14 Donor 16 Donor 22 Donor 26 Donor 19 Donor 1 Donor 7 Donor 2 Donor 8 Donor 4 Donor 2 Carrier Total LRRK2 Full Length Donor 25 Donor 8 Donor 2 Donor 3 Donor 15 Donor 4 Donor 24 Phospho-Ser935 LRRK2 Full Length Donor 7 Donor 19 Donor 2 Donor 26 Donor 25 Donor 2 Donor 3 Donor 4 Donor 8 Donor 15 Donor 24 Total Rab1 Donor 25 Donor 24 Donor 15 Donor 3 Total LRRK2/GAPDH (Full length) ps935 LRRK2/Total LRRK2 (Full length) Total Rab1/GAPDH 2.5 2. 1.5 1..5. Total LRRK2 2 kda species Donor 2 Donor 7 Donor 19 Donor 2 Donor 25 Donor 8 Donor 3 Donor 15 Donor 24 Donor 4 Total LRRK2/GAPDH (2 kda species) 2. 1.5 1..5. 1.5 1..5. 2. 1.5 1..5. Control Control Control Control G219S G219S G219S G219S Idiopathic Idiopathic Idiopathic Idiopathic

Figure 5 A B C D prab1/gapdh prab1/total Rab1 prab1/gapdh prab1/total Rab1 5 Control G219S 4 Idiopathic 3 2 1 Donor 13 Donor 11 Donor 21 3 Control G219S Idiopathic 2 1 6 4 2 6 4 2 Donor 6 Donor 18 Donor 13 Donor 13 Donor 11 Donor 6 Donor 6 Donor 13 Donor 18 Control G219S Idiopathic Control G219S Idiopathic Donor 6 Donor 1 Donor 18 Donor 5 Donor 23 Donor 9 Donor 12 Donor 17 Donor 14 Donor 16 Donor 1 Donor 26 Donor 11 Donor 12 Donor 14 Donor 16 Donor 1 Donor 21 Donor 5 Donor 23 Donor 9 Donor 17 Donor 18 Donor 1 Donor 23 Donor 21 Donor 14 Donor 5 Donor 9 Donor 17 Donor 12 Donor 2 Donor 1 Donor 19 Donor 16 Donor 1 Total phospho-rab1 vs GAPDH Carrier Donor 19 Donor 7 Donor 2 Donor 22 Donor 24 Donor 8 Donor 2 Donor 15 Donor 4 Donor 3 Donor 25 prab1/gapdh prab1/total Rab1 prab1/gapdh prab1/total Rab1 2. ** 1.5 1..5. Total phospho-rab1 vs Total Rab1 Donor 7 Donor 26 Donor 22 Donor 24 Donor 3 Donor 15 Donor 2 Donor 8 Donor 4 Donor 25 Donor 26 Donor 19 Donor 7 Donor 2 Donor 22 Donor 8 Donor 24 Donor 15 Donor 2 Donor 3 Donor 4 Donor 25 2. 1.5 1..5. 3 2 1 2.5 2. 1.5 1..5. Control Control LRRK2-dependent phospho-rab1 vs GAPDH Control LRRK2-dependent phospho-rab1 vs Total Rab1 Donor 11 Donor 14 Donor 16 Donor 12 Donor 1 Donor 23 Donor 17 Donor 9 Donor 5 Donor 21 Donor 2 Donor 1 Donor 7 Donor 19 Donor 26 Donor 22 Donor 3 Donor 15 Donor 24 Donor 2 Donor 8 Donor 4 Donor 25 Control ** G219S * G219S G219S ** G219S Idiopathic Idiopathic Idiopathic * Idiopathic

Figure 6 A Neutrophils PBMCs Donor 1 2 3 4 5 6 1 2 3 4 5 6 MLi-2: - + - + - + - + - + - + - + - + - + - + - + - + 25 prab1 25 15 25 25 15 LRRK2 ps935 Rab1 LRRK2 (C-Terminus) 37 GAPDH B Total LRRK2/GAPDH -+-+-+-+-+-+-+-+-+-+-+-+ Donor: 1 2 3 4 5 6 1 2 3 4 5 6 LRRK2 ps935/total LRRK2 3 2 1 2 1 2. 1.5 1..5. Total LRRK2 Full Length (i) Neutrophils Phospho-Ser935 LRRK2 Full Length (iii) -+-+-+-+-+-+-+-+-+-+-+-+ Donor: 1 2 3 4 5 6 1 2 3 4 5 6 Neutrophils PBMCs PBMCs Total Rab1/GAPDH 1.5 1..5. Total Rab1 (ii) -+-+-+-+-+-+-+-+-+-+-+-+ Donor: 1 2 3 4 5 6 1 2 3 4 5 6 prab1/total Rab1 Neutrophils PBMCs Phospho-Rab1 vs Total Rab1 (iv) 8 6 4 2 - + - + - + - + - + - + - + - + - + - + - + - + Donor: 1 2 3 4 5 6 1 2 3 4 5 6 Neutrophils PBMCs

Figure 7 A Conc. (nm): 25 25 25 25 MLi-2 3 1 3 1 3 PF-6447475 1 3 1 3 1 prab1 LRRK2 ps935 Rab1 LRRK2 (C-Terminus) B (i) prab1/total Rab1 1.5 1..5. Conc. (nm): B (ii) ps935/total LRRK2 1.5 1..5 MLi-2 PF-6447475 3 1 3 1 3 MLi-2 PF-6447475 1 3 1 3 1 37 GAPDH. Conc. (nm): 3 1 3 1 3 1 3 1 3 1 C D (i) Donor 1 Donor 2 MLi-2 (min): 1 3 5 1 3 5 25 25 prab1 LRRK2 ps935 prab1/total Rab1 1.5 1..5. MLi-2 (min): Donor 1 Donor 2 1 3 5 1 3 5 25 25 37 Rab1 LRRK2 (C-Terminus) GAPDH D (ii) ps935/total LRRK2 1.5 1..5. MLi-2 (min): Donor 1 Donor 2 1 3 5 1 3 5

Figure 8 A Donor 1 Donor 2 SDS: + + + + DIFP: + + + + MLi-2: - + - + - + - + - + - + 25 prab1 B Fresh: + + -2 C: + + -8 C: + + MLi-2: - + - + - + 25 prab1 25 LRRK2 ps935 25 LRRK2 ps935 25 Rab1 25 Rab1 25 LRRK2 (C-terminus) 25 LRRK2 (C-terminus) 37 GAPDH 37 GAPDH C Donor 1 Donor 2 Donor 1 Donor 2 DIFP (.5 mm): + + + + PMSF (2.5 mm): + + + + 25 prab1 25 LRRK2 ps935 25 Rab1 25 LRRK2 (C-Terminus) 37 GAPDH

Figure 9 A Time (h): 2 4 8 12 24 MLi-2: - + - + - + - + - + Donor 1 Donor 2 Donor 3 2 4 8 12 24 - + - + - + - + - + 2 4 8 12 24 - + - + - + - + - + 25 prab1 25 LRRK2 ps935 25 Rab1 25 LRRK2 (C-Terminus) 37 GAPDH B prab1/total Rab1 1.5 1..5. Donor 1 prab1/total Rab1 - + - + - + - + - + 1.5 1..5. Donor 2 prab1/total Rab1 - + - + - + - + - + 1.5 1..5. Donor 3 - + - + - + - + - + LRRK2 ps935/total LRRK2 1.5 1..5. LRRK2 ps935/total LRRK2 - + - + - + - + - + 1.5 1..5. LRRK2 ps935/total LRRK2 - + - + - + - + - + 1.5 1..5. - + - + - + - + - + Time (h): 2 4 8 12 24 2 4 8 12 24 2 4 8 12 24

Figure 1 Donor 1 2 3 4 5 6 7 8 9 1 11 12 MLi-2: - + - + - + - + - + - + - + - + - + - + - + - + Low prab1 Rab1 Exposure Medium prab1 Rab1 High prab1 Rab1 Phos-tag

Supplementary Figure 1 Rab1 MJFF-total Rab1 clone-1 2 g 5 g WT KO WT KO Rab1 rabbit mab CST #8127 2 g 5 g WT KO WT KO 25 kda 15 kda 1 kda 75 kda 5 kda 37 kda IB: Rab1 25 kda 2 kda 5 kda IB: Tubulin

Supplementary Figure 2 Donor 3 Gating around cells Live cell gating Granulocyte gating Side Scatter 25 2 15 1 5 98.7 % 5 1 15 2 25 DAPI 1 5 1 4 1 3 1 2 99.5 % Side Scatter 25 2 15 1 5 5 1 15 2 25 97.2 % 2.39 % 1 2 1 3 1 4 1 5 Forward Scatter Forward Scatter FITC (CD66b)

Supplementary Figure 3 A Donor 1 Live cell gating B cell and T cell gating Monocyte and granulocyte gating DAPI 1 5 1 4 1 3 Live Cells 99.9 % APC (CD19) 1 5 1 4 1 3 B cells 3.71 % * T cells 59.9 % V5 (CD14) 1 5 1 4 1 3 Monocytes 15.1 % 1 2 1 2 1 2 Granulocytes 1.2 % 5 1 15 2 25 Forward Scatter 1 2 1 3 1 4 1 5 PE (CD3) 1 2 1 3 1 4 1 5 FITC (CD66b) B * corresponds to the monocyte and granulocyte parent gate